ANI Pharmaceuticals (ANIP) Financials

$69.21 +0.01 (+0.01%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$69.22 +0.01 (+0.01%)

As of 04/17/2025 04:07 PM Eastern

Annual Income Statements for ANI Pharmaceuticals

This table shows ANI Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	29	15	3.93	-1.08	15	6.09	-23	-43	-50	17	-20
Consolidated Net Income / (Loss)	29	15	3.93	-1.08	15	6.09	-23	-43	-48	19	-19
Net Income / (Loss) Continuing Operations	29	15	3.93	-1.08	15	6.09	-23	-43	-48	19	-19
Total Pre-Tax Income	19	22	8.68	16	20	3.16	-26	-56	-63	20	-22
Total Operating Income	20	33	20	28	35	16	-16	-40	-35	47	0.58
Total Gross Profit	44	64	80	98	129	143	121	116	178	305	614
Total Revenue	56	76	129	177	202	207	208	216	316	487	614
Operating Revenue	56	76	129	177	202	207	208	216	316	487	614
Total Cost of Revenue	11	13	49	79	73	63	87	101	139	182	0.00
Total Operating Expenses	24	31	60	69	93	127	137	155	213	258	614
Selling, General & Admin Expense	18	21	28	32	44	56	65	84	124	162	250
Research & Development Expense	2.68	2.87	2.91	9.07	15	20	16	11	22	34	45
Depreciation Expense	3.88	6.90	22	28	34	45	45	47	57	60	68
Other Operating Expenses / (Income)	-	-	-	0.00	0.00	6.71	11	0.78	-	-	250
Impairment Charge	0.00	0.00	6.69	0.90	0.00	0.08	0.45	2.37	-	-	7.60
Restructuring Charge	-	-	-	-	-	-	0.00	0.00	5.68	1.13	0.00
Other Special Charges / (Income)	-	-	-	-	-	0.00	0.00	9.25	3.76	1.43	-5.97
Total Other Income / (Expense), net	-0.63	-11	-11	-12	-15	-13	-9.95	-16	-27	-27	-23
Interest Expense	-	-	-	-	-	-	-	-	0.00	0.00	7.47
Interest & Investment Income	-0.79	-11	-11	-12	-15	-13	-9.45	-12	-28	-27	-11
Other Income / (Expense), net	0.16	0.04	-0.07	0.06	-0.55	-0.23	-0.49	-4.34	0.67	-0.16	-4.03
Income Tax Expense	-9.37	6.36	4.74	17	4.56	-2.94	-3.41	-13	-15	1.09	-3.69
Preferred Stock Dividends Declared	-	-	-	-	-	0.00	0.00	0.19	1.63	1.63	1.63
Basic Earnings per Share	$2.61	$1.34	$0.34	($0.09)	$1.31	$0.51	($1.88)	($3.40)	($3.05)	$0.86	($1.04)
Weighted Average Basic Shares Outstanding	10.94M	11.37M	11.45M	11.55M	11.68M	11.84M	11.96M	12.60M	16.26M	18.00M	19.32M
Diluted Earnings per Share	$2.59	$1.32	$0.34	($0.09)	$1.30	$0.50	($1.88)	($3.40)	($3.05)	$0.85	($1.04)
Weighted Average Diluted Shares Outstanding	11.05M	11.56M	11.57M	11.55M	11.77M	12.04M	11.96M	12.60M	16.26M	18.19M	19.32M
Weighted Average Basic & Diluted Shares Outstanding	11.40M	11.50M	11.60M	12M	11.80M	12.11M	12.37M	17.27M	17.50M	21.08M	21.77M

This table shows ANI Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-9.01	-4.65	1.03	5.84	9.53	0.75	18	-2.69	-25	-11
Consolidated Net Income / (Loss)	-8.60	-4.24	1.44	6.25	9.94	1.16	18	-2.29	-24	-10
Net Income / (Loss) Continuing Operations	-8.60	-4.24	1.44	6.25	9.94	1.16	18	-2.29	-24	-10
Total Pre-Tax Income	-12	-5.73	2.17	5.25	12	0.95	25	-2.29	-31	-14
Total Operating Income	-5.00	1.82	9.90	12	18	6.73	20	5.17	-21	-4.38
Total Gross Profit	51	58	69	74	84	78	88	80	85	361
Total Revenue	84	94	107	117	132	132	137	138	148	191
Operating Revenue	84	94	107	117	132	132	137	138	148	191
Total Cost of Revenue	33	36	38	42	48	53	49	58	63	-170
Total Operating Expenses	56	56	59	62	66	72	68	75	106	365
Selling, General & Admin Expense	30	33	36	39	42	44	48	53	79	70
Research & Development Expense	7.66	5.22	5.92	7.37	11	9.87	11	7.30	10	17
Depreciation Expense	14	14	15	15	15	15	15	15	16	23
Other Special Charges / (Income)	2.48	1.62	0.96	1.04	-2.56	1.99	-5.26	0.36	0.83	-1.89
Total Other Income / (Expense), net	-7.23	-7.55	-7.73	-7.15	-6.44	-5.78	5.02	-7.46	-11	-9.38
Interest & Investment Income	-7.26	-7.51	-7.70	-7.10	-6.40	-5.75	-4.60	-4.66	-2.33	0.29
Other Income / (Expense), net	0.04	-0.04	-0.03	-0.05	-0.04	-0.03	9.62	-2.80	-1.18	-9.68
Income Tax Expense	-3.62	-1.49	0.73	-1.00	1.57	-0.21	7.13	0.00	-7.33	-3.49
Preferred Stock Dividends Declared	0.41	0.41	0.41	0.41	0.41	0.41	0.41	0.41	0.41	0.41
Basic Earnings per Share	($0.55)	($0.29)	$0.06	$0.30	$0.46	$0.04	$0.84	($0.14)	($1.27)	($0.47)
Weighted Average Basic Shares Outstanding	16.30M	16.26M	16.39M	17.69M	18.88M	18.00M	19.10M	19.32M	19.40M	19.32M
Diluted Earnings per Share	($0.55)	($0.29)	$0.06	$0.29	$0.45	$0.05	$0.82	($0.14)	($1.27)	($0.45)
Weighted Average Diluted Shares Outstanding	16.30M	16.26M	16.53M	17.86M	19.13M	18.19M	19.42M	19.32M	19.40M	19.32M
Weighted Average Basic & Diluted Shares Outstanding	17.46M	17.50M	17.97M	20.29M	20.44M	21.08M	20.97M	21.04M	21.03M	21.77M

This table details how cash moves in and out of ANI Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	158	-14	-122	3.78	12	19	-54	92	-52	168	-76
Net Cash From Operating Activities	22	17	27	39	67	46	15	3.32	-31	119	64
Net Cash From Continuing Operating Activities	22	17	27	39	67	46	15	3.32	-31	119	64
Net Income / (Loss) Continuing Operations	29	15	3.93	-1.08	15	6.09	-23	-43	-48	19	-19
Consolidated Net Income / (Loss)	29	15	3.93	-1.08	15	6.09	-23	-43	-48	19	-19
Depreciation Expense	3.88	6.90	22	28	34	45	45	47	60	60	68
Amortization Expense	0.56	6.83	7.28	7.67	8.47	7.02	1.88	2.51	3.96	3.92	14
Non-Cash Adjustments To Reconcile Net Income	6.14	7.43	19	12	11	13	26	16	23	21	49
Changes in Operating Assets and Liabilities, net	-17	-19	-25	-7.55	-1.79	-25	-35	-20	-70	16	-48
Net Cash From Investing Activities	-36	-33	-149	-108	-27	-28	-68	-105	-16	-19	-405
Net Cash From Continuing Investing Activities	-36	-33	-149	-108	-27	-28	-68	-105	-16	-19	-405
Purchase of Property, Plant & Equipment	-1.12	-2.18	-4.57	-10	-5.74	-6.64	-6.14	-2.56	-8.88	-8.87	-16
Acquisitions	-35	-31	-144	-98	-22	-21	-62	-106	-7.61	-9.64	-402
Sale of Property, Plant & Equipment	-	-	-	-	-	0.00	0.00	2.65	0.75	0.00	14
Net Cash From Financing Activities	172	1.07	-0.73	72	-28	1.25	-1.44	195	-5.13	67	265
Net Cash From Continuing Financing Activities	172	1.07	-0.73	72	-28	1.25	-1.44	195	-5.13	67	265
Repayment of Debt	0.00	0.00	-0.29	-2.74	-31	-121	-16	75	-3.00	-3.00	-313
Repurchase of Common Equity	0.00	0.00	-2.50	-	-	-1.03	-1.52	-0.89	-1.96	-4.99	-11
Payment of Dividends	-	-	-	-	-	0.00	0.00	-0.19	-1.63	-1.63	-1.63
Issuance of Debt	138	0.00	0.00	75	0.00	118	15	24	0.00	0.00	641
Issuance of Common Equity	47	-	-	-	-	0.00	0.00	70	0.00	81	0.00
Other Financing Activities, net	-13	1.07	2.07	0.09	2.69	5.74	0.62	2.07	1.46	-3.50	-50
Effect of Exchange Rate Changes	-	-	-	-	-	-	-	-	0.00	0.00	-0.47
Cash Interest Paid	0.00	4.15	4.08	3.76	6.29	6.09	6.93	9.71	21	31	24
Cash Income Taxes Paid	0.15	13	9.54	18	6.40	10	4.98	10	0.29	1.23	19

This table details how cash moves in and out of ANI Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-7.10	-8.05	15	94	31	28	7.48	12	-95	-0.12
Net Cash From Operating Activities	3.62	-4.40	21	21	32	45	18	17	12	16
Net Cash From Continuing Operating Activities	3.62	-4.40	21	21	32	45	18	17	12	16
Net Income / (Loss) Continuing Operations	-8.60	-4.24	1.44	6.25	9.94	1.16	18	-2.29	-24	-10
Consolidated Net Income / (Loss)	-8.60	-4.24	1.44	6.25	9.94	1.16	18	-2.29	-24	-10
Depreciation Expense	15	16	15	15	15	15	15	15	16	23
Amortization Expense	0.99	1.00	0.99	0.99	1.00	0.95	0.10	0.10	3.35	11
Non-Cash Adjustments To Reconcile Net Income	5.89	7.21	3.75	5.46	4.14	7.57	-10	14	17	28
Changes in Operating Assets and Liabilities, net	-10	-24	0.55	-6.75	1.88	20	-4.46	-9.22	0.08	-35
Net Cash From Investing Activities	-9.81	-3.14	-2.35	-6.83	-4.55	-4.78	8.93	-4.45	-399	-11
Net Cash From Continuing Investing Activities	-9.81	-3.14	-2.35	-6.83	-4.55	-4.78	8.93	-4.45	-399	-11
Purchase of Property, Plant & Equipment	-2.47	-3.14	-2.35	-2.50	-1.74	-2.28	-4.58	-4.45	-4.81	-2.39
Acquisitions	-7.35	-0.00	-0.00	-4.33	-2.81	-2.50	0.00	-	-394	-8.29
Net Cash From Financing Activities	-0.91	-0.51	-4.55	80	3.76	-12	-20	-1.45	291	-4.91
Net Cash From Continuing Financing Activities	-0.91	-0.51	-4.55	80	3.76	-12	-20	-1.45	291	-4.91
Repayment of Debt	-0.75	-0.75	-0.75	-0.75	-0.75	-0.75	-0.75	-0.75	-308	-4.01
Repurchase of Common Equity	-0.24	-0.12	-3.55	-0.54	-0.67	-0.23	-8.66	-1.30	-0.68	-0.32
Payment of Dividends	-0.41	-0.41	-0.41	-0.41	-0.41	-0.41	-0.41	-0.41	-0.41	-0.41
Other Financing Activities, net	0.48	0.77	0.16	1.29	5.58	-11	-9.91	1.01	-41	-0.18
Effect of Exchange Rate Changes	-	-	-	-	-	-	-	-	-	-0.40
Cash Interest Paid	2.63	7.45	4.29	11	7.97	8.01	7.95	8.21	3.08	5.15
Cash Income Taxes Paid	0.03	0.13	2.74	-2.60	0.79	0.30	0.85	16	0.01	1.85

This table presents ANI Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	260	285	323	412	431	457	461	772	760	904	1,284
Total Current Assets	195	193	103	132	153	188	170	322	344	520	528
Cash & Equivalents	169	155	27	31	43	62	7.86	100	48	221	145
Restricted Cash	-	-	-	-	-	-	-	0.00	5.01	0.00	0.03
Short-Term Investments	-	-	-	-	-	-	-	-	-	0.00	6.31
Accounts Receivable	17	22	46	59	65	72	96	129	165	162	222
Inventories, net	7.52	13	26	38	41	48	61	82	105	111	137
Prepaid Expenses	1.14	1.45	3.56	2.78	4.52	5.07	5.86	11	12	17	18
Other Current Assets	-	-	-	-	-	-	-	0.00	8.02	8.02	0.00
Plant, Property, & Equipment, net	5.22	7.13	11	20	38	41	41	53	43	45	57
Total Noncurrent Assets	59	86	209	260	240	229	250	397	373	340	699
Goodwill	1.84	1.84	1.84	1.84	3.58	3.58	3.58	28	28	28	60
Intangible Assets	42	66	176	230	202	180	189	294	252	209	542
Noncurrent Deferred & Refundable Income Taxes	15	17	26	23	28	38	52	68	81	91	85
Other Noncurrent Operating Assets	-	-	0.00	0.83	1.47	1.22	0.80	2.21	11	12	12
Total Liabilities & Shareholders' Equity	260	285	323	412	431	457	461	772	760	904	1,284
Total Liabilities	120	125	153	237	233	244	265	413	422	447	855
Total Current Liabilities	13	12	32	39	166	62	79	88	99	145	194
Short-Term Debt	-	-	0.00	3.35	3.26	9.94	13	0.85	0.85	13	9.20
Accounts Payable	2.65	2.07	3.39	3.63	8.88	15	11	23	29	37	46
Accrued Expenses	3.53	5.85	19	22	19	16	17	19	26	34	55
Current Deferred & Payable Income Tax Liabilities	4.25	0.00	2.40	0.00	5.02	0.00	3.91	-	0.00	8.16	6.75
Current Employee Benefit Liabilities	1.35	1.19	1.63	2.31	3.52	3.74	6.23	8.52	10	24	38
Other Current Liabilities	1.45	2.65	5.76	8.27	125	17	27	36	33	30	39
Total Noncurrent Liabilities	107	113	121	198	68	182	187	325	322	301	661
Long-Term Debt	107	113	121	198	67	176	172	287	286	285	615
Other Noncurrent Operating Liabilities	-	0.00	0.63	0.00	0.50	6.51	14	39	36	17	47
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	-	-	-	-	-	-	-	25	25	25	25
Total Equity & Noncontrolling Interests	140	160	170	175	197	213	196	334	314	433	404
Total Preferred & Common Equity	140	160	170	175	197	213	196	334	314	433	404
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	140	160	170	175	197	213	196	334	314	433	404
Common Stock	160	164	173	179	187	201	214	388	404	514	520
Retained Earnings	-20	-4.35	-2.92	-4.01	11	18	-4.97	-48	-97	-80	-100
Treasury Stock	-	-	0.00	-0.26	-0.66	-0.72	-2.25	-3.14	-5.09	-10	-21
Accumulated Other Comprehensive Income / (Loss)	-	-	-	0.00	-0.38	-4.87	-11	-3.06	12	8.86	5.34
Other Equity Adjustments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

This table presents ANI Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	739	765	859	890	915	921	1,287
Total Current Assets	309	365	459	497	541	555	521
Cash & Equivalents	56	68	162	193	229	240	145
Restricted Cash	-	0.00	0.00	0.00	-	-	0.04
Short-Term Investments	-	-	-	-	9.66	6.94	8.30
Accounts Receivable	140	175	173	179	172	166	196
Inventories, net	96	104	104	107	114	125	148
Prepaid Expenses	8.75	11	12	11	16	17	24
Other Current Assets	8.02	8.02	8.02	8.02	0.00	0.00	0.00
Plant, Property, & Equipment, net	43	43	44	44	49	52	57
Total Noncurrent Assets	387	357	356	349	325	314	709
Goodwill	28	28	28	28	28	28	60
Intangible Assets	264	239	230	220	196	183	570
Noncurrent Deferred & Refundable Income Taxes	77	81	82	84	88	90	68
Other Noncurrent Operating Assets	12	9.23	16	16	14	13	11
Total Liabilities & Shareholders' Equity	739	765	859	890	915	921	1,287
Total Liabilities	402	426	425	435	438	440	857
Total Current Liabilities	82	126	123	134	137	140	190
Short-Term Debt	0.85	24	26	25	1.26	1.69	8.44
Accounts Payable	19	33	29	34	49	49	61
Accrued Expenses	20	22	27	28	32	40	54
Current Deferred & Payable Income Tax Liabilities	-	-	-	0.59	11	0.00	0.00
Current Employee Benefit Liabilities	7.75	13	11	15	9.53	16	30
Other Current Liabilities	34	34	30	31	33	34	37
Total Noncurrent Liabilities	321	300	302	301	301	300	667
Long-Term Debt	286	285	285	285	285	284	618
Other Noncurrent Operating Liabilities	35	14	17	16	16	16	48
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	25	25	25	25	25	25	25
Total Equity & Noncontrolling Interests	312	315	410	430	452	456	406
Total Preferred & Common Equity	312	315	410	430	452	456	406
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	312	315	410	430	452	456	406
Common Stock	399	408	495	507	524	532	511
Retained Earnings	-93	-96	-90	-81	-62	-65	-90
Treasury Stock	-4.98	-8.64	-9.18	-9.85	-19	-20	-21
Accumulated Other Comprehensive Income / (Loss)	10	11	14	14	9.41	8.33	5.37
Other Equity Adjustments	0.00	0.00	0.00	0.00	0.00	0.00	0.00

This table displays calculated financial ratios and metrics derived from ANI Pharmaceuticals' official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	86.06%	36.36%	68.53%	37.49%	13.99%	2.47%	0.93%	3.67%	46.38%	53.87%	26.20%
EBITDA Growth	1,181.41%	88.89%	6.79%	28.91%	20.38%	-12.02%	-55.72%	-81.24%	415.30%	281.11%	-28.95%
EBIT Growth	3,300.67%	62.36%	-38.90%	41.88%	22.64%	-53.68%	-202.40%	-167.33%	21.58%	235.24%	-107.37%
NOPAT Growth	3,828.35%	-22.05%	-60.65%	-120.48%	1,565.46%	15.52%	-135.52%	-148.46%	11.33%	279.72%	-99.08%
Net Income Growth	9,450.50%	-46.52%	-74.41%	-127.35%	1,539.96%	-60.67%	-470.00%	-88.94%	-12.42%	139.21%	-198.63%
EPS Growth	381.52%	-49.03%	-74.24%	-126.47%	1,544.44%	-61.54%	-476.00%	-80.85%	10.29%	127.87%	-222.35%
Operating Cash Flow Growth	501.77%	-21.64%	59.13%	43.49%	70.16%	-31.97%	-66.54%	-78.24%	-1,039.28%	481.24%	-46.19%
Free Cash Flow Firm Growth	73.88%	-3.66%	-606.37%	35.34%	275.66%	-154.07%	39.18%	-312.24%	72.16%	246.82%	-548.20%
Invested Capital Growth	158.86%	53.74%	117.06%	31.87%	-35.38%	50.68%	11.27%	46.75%	5.74%	-6.54%	68.68%
Revenue Q/Q Growth	23.11%	-3.78%	18.60%	5.41%	5.13%	-4.24%	4.66%	1.73%	11.76%	8.33%	10.61%
EBITDA Q/Q Growth	55.42%	-5.35%	-2.26%	13.11%	7.52%	-18.71%	22.61%	-80.74%	2,362.17%	4.24%	-4.38%
EBIT Q/Q Growth	57.58%	-12.30%	-20.04%	27.49%	11.50%	-49.41%	23.08%	-151.47%	44.89%	11.73%	-119.94%
NOPAT Q/Q Growth	169.08%	-47.49%	-36.52%	-111.66%	3,324.49%	7.85%	23.80%	-152.83%	41.99%	4.07%	-95.00%
Net Income Q/Q Growth	157.24%	-54.11%	-50.14%	-114.40%	3,461.84%	-62.75%	5.05%	-92.76%	29.35%	40.34%	-161.20%
EPS Q/Q Growth	161.62%	-55.10%	-50.00%	-114.29%	6,400.00%	-62.96%	4.57%	-85.79%	34.13%	66.67%	-92.59%
Operating Cash Flow Q/Q Growth	161.46%	-25.92%	36.73%	10.43%	20.53%	-32.95%	-40.78%	-66.10%	19.97%	70.38%	-31.09%
Free Cash Flow Firm Q/Q Growth	40.39%	-57.65%	1.50%	-194.16%	496.53%	-149.62%	69.15%	-733.51%	75.94%	145.49%	-12.98%
Invested Capital Q/Q Growth	19.93%	-1.12%	-3.21%	9.34%	-37.04%	52.29%	2.33%	44.94%	1.73%	-6.48%	-0.30%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	79.50%	83.37%	62.07%	55.31%	63.77%	69.42%	58.19%	53.45%	56.13%	62.71%	100.00%
EBITDA Margin	43.96%	60.89%	38.59%	36.18%	38.21%	32.81%	14.39%	2.60%	9.17%	22.70%	12.78%
Operating Margin	35.74%	42.84%	15.61%	16.02%	17.54%	7.92%	-7.68%	-18.41%	-11.15%	9.65%	0.10%
EBIT Margin	36.03%	42.90%	15.55%	16.05%	17.27%	7.81%	-7.92%	-20.42%	-10.94%	9.62%	-0.56%
Profit (Net Income) Margin	51.36%	20.14%	3.06%	-0.61%	7.69%	2.95%	-10.82%	-19.71%	-15.14%	3.86%	-3.01%
Tax Burden Percent	148.34%	70.75%	45.33%	-6.58%	77.27%	193.03%	86.85%	76.00%	76.43%	94.50%	83.39%
Interest Burden Percent	96.10%	66.38%	43.38%	57.60%	57.60%	19.58%	157.25%	127.01%	181.04%	42.45%	644.01%
Effective Tax Rate	-48.34%	29.26%	54.67%	106.58%	22.73%	-93.03%	0.00%	0.00%	0.00%	5.50%	0.00%
Return on Invested Capital (ROIC)	55.40%	23.59%	4.83%	-0.62%	9.76%	11.46%	-3.20%	-6.13%	-4.44%	8.02%	0.06%
ROIC Less NNEP Spread (ROIC-NNEP)	57.92%	38.55%	-17.15%	0.00%	-2.83%	-24.69%	-10.99%	-14.44%	-15.61%	-8.49%	-6.83%
Return on Net Nonoperating Assets (RNNOA)	-23.59%	-13.34%	-2.45%	0.00%	-1.43%	-8.48%	-7.84%	-9.24%	-9.30%	-3.31%	-4.24%
Return on Equity (ROE)	31.81%	10.25%	2.39%	-0.62%	8.33%	2.97%	-11.04%	-15.37%	-13.74%	4.72%	-4.18%
Cash Return on Invested Capital (CROIC)	-33.14%	-18.77%	-69.01%	-28.11%	52.74%	-28.98%	-13.88%	-44.02%	-10.01%	14.79%	-51.07%
Operating Return on Assets (OROA)	13.26%	12.02%	6.58%	7.72%	8.26%	3.63%	-3.60%	-7.16%	-4.52%	5.62%	-0.32%
Return on Assets (ROA)	18.91%	5.64%	1.29%	-0.29%	3.68%	1.37%	-4.91%	-6.91%	-6.25%	2.26%	-1.69%
Return on Common Equity (ROCE)	31.81%	10.25%	2.39%	-0.62%	8.33%	2.97%	-11.04%	-14.68%	-12.76%	4.42%	-3.95%
Return on Equity Simple (ROE_SIMPLE)	20.57%	9.60%	2.32%	-0.62%	7.85%	2.86%	-11.52%	-12.76%	-15.27%	4.34%	-4.59%
Net Operating Profit after Tax (NOPAT)	30	23	9.10	-1.86	27	32	-11	-28	-25	44	0.41
NOPAT Margin	53.02%	30.31%	7.08%	-1.05%	13.55%	15.28%	-5.38%	-12.89%	-7.81%	9.12%	0.07%
Net Nonoperating Expense Percent (NNEP)	-2.53%	-14.96%	21.98%	-0.62%	12.59%	36.15%	7.79%	8.31%	11.17%	16.52%	6.89%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-4.11%	6.07%	0.04%
Cost of Revenue to Revenue	20.50%	16.63%	37.93%	44.69%	36.23%	30.58%	41.81%	46.55%	43.87%	37.29%	0.00%
SG&A Expenses to Revenue	32.04%	27.72%	21.64%	17.86%	21.86%	27.04%	31.17%	39.00%	39.21%	33.22%	40.63%
R&D to Revenue	4.78%	3.77%	2.26%	5.13%	7.63%	9.59%	7.68%	5.26%	7.05%	7.04%	7.26%
Operating Expenses to Revenue	43.76%	40.53%	46.46%	39.29%	46.23%	61.51%	65.88%	71.86%	67.25%	53.07%	99.90%
Earnings before Interest and Taxes (EBIT)	20	33	20	28	35	16	-17	-44	-35	47	-3.45
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	25	46	50	64	77	68	30	5.63	29	111	79
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.57	3.24	4.14	4.30	2.71	3.50	1.83	1.76	2.24	2.60	2.88
Price to Tangible Book Value (P/TBV)	6.66	5.65	0.00	0.00	0.00	25.87	99.44	49.46	20.77	5.76	0.00
Price to Revenue (P/Rev)	11.41	6.80	5.46	4.25	2.65	3.61	1.72	2.72	2.22	2.31	1.89
Price to Earnings (P/E)	22.22	33.75	178.61	0.00	34.45	122.36	0.00	0.00	0.00	65.69	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	4.50%	2.96%	0.56%	0.00%	2.90%	0.82%	0.00%	0.00%	0.00%	1.52%	0.00%
Enterprise Value to Invested Capital (EV/IC)	7.46	4.02	3.09	2.71	2.55	2.62	1.46	1.48	1.68	2.30	1.84
Enterprise Value to Revenue (EV/Rev)	10.30	6.26	6.19	5.21	2.78	4.21	2.57	3.70	3.04	2.52	2.70
Enterprise Value to EBITDA (EV/EBITDA)	23.43	10.28	16.04	14.40	7.29	12.83	17.89	142.06	33.13	11.12	21.14
Enterprise Value to EBIT (EV/EBIT)	28.58	14.59	39.79	32.46	16.13	53.90	0.00	0.00	0.00	26.25	0.00
Enterprise Value to NOPAT (EV/NOPAT)	19.42	20.65	87.44	0.00	20.55	27.53	0.00	0.00	0.00	27.68	4,061.24
Enterprise Value to Operating Cash Flow (EV/OCF)	26.16	27.67	28.97	23.38	8.37	19.05	35.15	240.67	0.00	10.33	25.93
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	3.80	0.00	0.00	0.00	0.00	15.02	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.76	0.71	0.71	1.15	0.36	0.87	0.95	0.80	0.85	0.65	1.46
Long-Term Debt to Equity	0.76	0.71	0.71	1.13	0.34	0.83	0.88	0.80	0.84	0.62	1.44
Financial Leverage	-0.41	-0.35	0.14	0.74	0.51	0.34	0.71	0.64	0.60	0.39	0.62
Leverage Ratio	1.68	1.82	1.84	2.13	2.27	2.16	2.25	2.22	2.20	2.09	2.47
Compound Leverage Factor	1.62	1.21	0.80	1.23	1.30	0.42	3.53	2.82	3.98	0.89	15.90
Debt to Total Capital	43.25%	41.47%	41.56%	53.55%	26.34%	46.61%	48.69%	44.48%	45.84%	39.43%	59.29%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.89%	1.22%	2.49%	3.47%	0.13%	0.14%	1.74%	0.87%
Long-Term Debt to Total Capital	43.25%	41.47%	41.56%	52.66%	25.13%	44.11%	45.21%	44.35%	45.70%	37.70%	58.42%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3.85%	3.98%	3.29%	2.36%
Common Equity to Total Capital	56.75%	58.53%	58.44%	46.45%	73.66%	53.39%	51.31%	51.68%	50.19%	57.28%	38.35%
Debt to EBITDA	4.33	2.44	2.43	3.15	0.92	2.74	6.19	51.06	9.88	2.70	7.95
Net Debt to EBITDA	-2.54	-0.89	1.88	2.66	0.36	1.82	5.93	33.24	8.04	0.70	6.02
Long-Term Debt to EBITDA	4.33	2.44	2.43	3.10	0.87	2.59	5.75	50.91	9.85	2.58	7.83
Debt to NOPAT	3.59	4.90	13.25	-108.08	2.58	5.89	-16.56	-10.32	-11.60	6.71	1,526.71
Net Debt to NOPAT	-2.11	-1.78	10.25	-91.37	1.01	3.91	-15.86	-6.72	-9.45	1.73	1,156.85
Long-Term Debt to NOPAT	3.59	4.90	13.25	-106.28	2.46	5.57	-15.38	-10.29	-11.57	6.42	1,504.21
Altman Z-Score	4.41	3.87	3.61	2.81	2.11	2.79	1.37	1.22	1.47	2.60	1.49
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	4.48%	7.13%	6.24%	5.61%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	14.74	16.38	3.22	3.35	0.92	3.04	2.17	3.68	3.46	3.57	2.72
Quick Ratio	14.08	15.02	2.29	2.29	0.65	2.18	1.32	2.61	2.15	2.63	1.93
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-18	-18	-130	-84	148	-80	-49	-200	-56	82	-367
Operating Cash Flow to CapEx	1,967.23%	790.84%	601.66%	380.16%	1,167.93%	687.73%	248.85%	0.00%	-383.99%	1,341.44%	2,351.84%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-49.09
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.57
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.21
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.37	0.28	0.42	0.48	0.48	0.47	0.45	0.35	0.41	0.58	0.56
Accounts Receivable Turnover	3.76	3.89	3.79	3.38	3.26	3.02	2.48	1.93	2.15	2.97	3.20
Inventory Turnover	2.08	1.21	2.47	2.47	1.87	1.42	1.60	1.41	1.48	1.68	0.00
Fixed Asset Turnover	11.47	12.36	14.19	11.26	6.89	5.25	5.10	4.60	6.60	11.08	12.11
Accounts Payable Turnover	5.62	5.38	17.88	22.52	11.67	5.38	6.74	5.88	5.31	5.50	0.00
Days Sales Outstanding (DSO)	97.20	93.80	96.24	108.03	111.93	121.02	147.00	189.41	169.57	122.78	114.01
Days Inventory Outstanding (DIO)	175.55	300.60	148.04	147.58	195.51	256.22	228.17	258.48	245.97	217.73	0.00
Days Payable Outstanding (DPO)	64.95	67.87	20.41	16.21	31.27	67.88	54.16	62.09	68.74	66.35	0.00
Cash Conversion Cycle (CCC)	207.80	326.53	223.87	239.40	276.17	309.37	321.00	385.80	346.80	274.16	114.01
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	77	119	258	340	220	331	369	541	572	534	901
Invested Capital Turnover	1.04	0.78	0.68	0.59	0.72	0.75	0.60	0.48	0.57	0.88	0.86
Increase / (Decrease) in Invested Capital	47	42	139	82	-120	111	37	172	31	-37	367
Enterprise Value (EV)	576	478	796	921	561	869	537	800	961	1,229	1,660
Market Capitalization	639	519	703	751	534	746	359	588	703	1,127	1,162
Book Value per Share	$12.34	$13.92	$14.64	$15.00	$16.64	$17.60	$15.84	$26.18	$17.96	$21.17	$19.20
Tangible Book Value per Share	$8.46	$7.99	($0.69)	($4.88)	($0.67)	$2.38	$0.29	$0.93	$1.94	$9.57	($9.42)
Total Capital	246	274	290	376	268	399	381	646	625	756	1,053
Total Debt	107	113	121	202	71	186	186	287	287	298	624
Total Long-Term Debt	107	113	121	198	67	176	172	287	286	285	615
Net Debt	-62	-41	93	170	28	123	178	187	233	77	473
Capital Expenditures (CapEx)	1.12	2.18	4.57	10	5.74	6.64	6.14	-0.09	8.13	8.87	2.72
Debt-free, Cash-free Net Working Capital (DFCFNWC)	13	26	44	65	-52	74	97	135	192	166	192
Debt-free Net Working Capital (DFNWC)	182	181	71	96	-9.42	136	105	235	246	387	343
Net Working Capital (NWC)	182	181	71	92	-13	126	92	234	245	374	334
Net Nonoperating Expense (NNE)	0.93	7.76	5.17	-0.79	12	25	11	15	23	26	19
Net Nonoperating Obligations (NNO)	-62	-41	88	165	23	118	173	182	233	77	473
Total Depreciation and Amortization (D&A)	4.44	14	30	36	42	52	47	50	64	64	82
Debt-free, Cash-free Net Working Capital to Revenue	22.73%	34.25%	33.97%	36.52%	-26.01%	35.65%	46.59%	62.36%	60.82%	34.17%	31.25%
Debt-free Net Working Capital to Revenue	324.74%	236.93%	55.25%	54.13%	-4.67%	65.83%	50.37%	108.77%	77.65%	79.59%	55.86%
Net Working Capital to Revenue	324.74%	236.93%	55.25%	52.24%	-6.29%	61.01%	44.01%	108.38%	77.38%	76.90%	54.36%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$2.61	$1.34	$0.34	($0.09)	$1.31	$0.51	($1.88)	($3.40)	($3.05)	$0.86	($1.04)
Adjusted Weighted Average Basic Shares Outstanding	10.94M	11.37M	11.45M	11.55M	11.68M	11.84M	11.96M	12.60M	16.26M	18.00M	19.32M
Adjusted Diluted Earnings per Share	$2.59	$1.32	$0.34	($0.09)	$1.30	$0.50	($1.88)	($3.40)	($3.05)	$0.85	($1.04)
Adjusted Weighted Average Diluted Shares Outstanding	11.05M	11.56M	11.57M	11.55M	11.77M	12.04M	11.96M	12.60M	16.26M	18.19M	19.32M
Adjusted Basic & Diluted Earnings per Share	$0.00	$1.34	$0.00	$0.00	$0.00	$0.51	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	11.40M	11.46M	11.60M	11.66M	11.86M	12.11M	12.37M	17.27M	17.50M	21.08M	21.77M
Normalized Net Operating Profit after Tax (NOPAT)	14	23	19	20	27	11	-11	-20	-18	47	1.55
Normalized NOPAT Margin	25.02%	30.31%	14.57%	11.57%	13.55%	5.57%	-5.23%	-9.12%	-5.72%	9.61%	0.25%
Pre Tax Income Margin	34.62%	28.48%	6.75%	9.25%	9.95%	1.53%	-12.45%	-25.94%	-19.81%	4.08%	-3.62%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.46
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.83
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.31
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.45%	-3.39%	8.65%	-8.77%
Augmented Payout Ratio	0.00%	0.00%	63.55%	0.00%	0.00%	16.92%	-6.75%	-2.54%	-7.48%	35.21%	-67.94%

This table displays calculated financial ratios and metrics derived from ANI Pharmaceuticals' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	61.01%	54.66%	65.62%	57.81%	57.27%	39.71%	28.70%	18.44%	12.52%	44.75%
EBITDA Growth	56.19%	253.73%	782.19%	830.44%	199.60%	24.48%	75.05%	-38.76%	-107.64%	-15.74%
EBIT Growth	-7.01%	106.73%	151.14%	201.65%	461.21%	276.43%	203.57%	-80.82%	-221.16%	-309.98%
NOPAT Growth	-40.23%	107.67%	148.95%	263.24%	543.26%	543.90%	121.95%	-75.48%	-192.68%	-137.36%
Net Income Growth	-93.39%	82.42%	107.15%	141.85%	215.58%	127.22%	1,165.25%	-136.62%	-343.12%	-989.70%
EPS Growth	-48.65%	84.49%	104.72%	130.85%	181.82%	117.24%	1,266.67%	-148.28%	-382.22%	-1,000.00%
Operating Cash Flow Growth	167.07%	63.89%	213.10%	279.61%	787.91%	1,116.82%	-14.73%	-15.57%	-61.22%	-64.55%
Free Cash Flow Firm Growth	-1,142.75%	84.25%	88.99%	93.10%	103.20%	253.37%	410.18%	598.54%	-5,726.90%	-911.35%
Invested Capital Growth	50.65%	5.74%	5.34%	5.11%	1.66%	-6.54%	-9.70%	-11.00%	58.22%	68.68%
Revenue Q/Q Growth	13.49%	12.42%	13.32%	9.14%	13.11%	-0.13%	4.39%	0.44%	7.46%	28.48%
EBITDA Q/Q Growth	278.02%	61.15%	39.24%	9.70%	21.72%	-33.05%	95.82%	-61.63%	-115.18%	838.45%
EBIT Q/Q Growth	59.19%	135.86%	454.61%	25.23%	45.02%	-62.63%	347.26%	-92.09%	-1,015.96%	35.23%
NOPAT Q/Q Growth	61.32%	136.44%	416.24%	124.35%	5.04%	-47.07%	77.94%	-75.21%	-496.96%	78.66%
Net Income Q/Q Growth	42.37%	50.66%	133.91%	333.98%	59.17%	-88.38%	1,476.36%	-112.56%	-956.67%	57.48%
EPS Q/Q Growth	41.49%	47.27%	120.69%	383.33%	55.17%	-88.89%	1,540.00%	-117.07%	-807.14%	64.57%
Operating Cash Flow Q/Q Growth	131.55%	-221.45%	586.91%	-3.72%	55.96%	39.08%	-59.17%	-4.68%	-28.37%	27.14%
Free Cash Flow Firm Q/Q Growth	2.39%	84.55%	23.08%	40.50%	145.31%	639.61%	55.56%	-4.37%	-611.40%	-6.65%
Invested Capital Q/Q Growth	1.19%	1.73%	1.57%	0.53%	-2.13%	-6.48%	-1.87%	-0.91%	73.99%	-0.30%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	60.76%	61.45%	64.69%	63.72%	63.51%	59.42%	64.23%	58.20%	57.48%	189.17%
EBITDA Margin	13.58%	19.47%	23.92%	24.05%	25.88%	17.35%	32.54%	12.43%	-1.76%	10.10%
Operating Margin	-5.96%	1.93%	9.27%	10.64%	13.61%	5.11%	14.78%	3.74%	-13.83%	-2.30%
EBIT Margin	-5.92%	1.89%	9.23%	10.60%	13.59%	5.08%	21.78%	1.72%	-14.63%	-7.37%
Profit (Net Income) Margin	-10.26%	-4.50%	1.35%	5.36%	7.54%	0.88%	13.25%	-1.66%	-16.29%	-5.39%
Tax Burden Percent	70.36%	74.07%	66.47%	118.98%	86.35%	121.96%	71.87%	100.00%	76.72%	74.67%
Interest Burden Percent	246.51%	-322.16%	21.96%	42.51%	64.27%	14.15%	84.63%	-96.54%	145.16%	97.92%
Effective Tax Rate	0.00%	0.00%	33.53%	-18.98%	13.65%	-21.96%	28.14%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-2.53%	0.77%	3.90%	8.92%	9.32%	5.48%	9.95%	2.56%	-7.29%	-1.38%
ROIC Less NNEP Spread (ROIC-NNEP)	-5.03%	-1.89%	1.60%	4.29%	6.07%	0.94%	12.44%	-3.71%	-10.61%	-4.00%
Return on Net Nonoperating Assets (RNNOA)	-3.88%	-1.12%	1.04%	2.05%	2.63%	0.37%	4.40%	-0.76%	-7.07%	-2.48%
Return on Equity (ROE)	-6.41%	-0.36%	4.95%	10.97%	11.95%	5.85%	14.35%	1.80%	-14.36%	-3.86%
Cash Return on Invested Capital (CROIC)	-49.52%	-10.01%	-5.97%	-2.63%	5.88%	14.79%	18.78%	18.56%	-43.98%	-51.07%
Operating Return on Assets (OROA)	-2.77%	0.78%	4.39%	5.28%	7.50%	2.97%	13.42%	1.04%	-7.46%	-4.14%
Return on Assets (ROA)	-4.80%	-1.86%	0.64%	2.67%	4.16%	0.51%	8.16%	-1.00%	-8.31%	-3.03%
Return on Common Equity (ROCE)	-6.10%	-0.33%	4.59%	10.26%	11.20%	5.48%	13.48%	1.70%	-13.56%	-3.64%
Return on Equity Simple (ROE_SIMPLE)	-21.74%	0.00%	-8.37%	-1.26%	3.11%	0.00%	7.87%	5.93%	-1.75%	0.00%
Net Operating Profit after Tax (NOPAT)	-3.50	1.27	6.58	15	15	8.20	15	3.62	-14	-3.06
NOPAT Margin	-4.17%	1.35%	6.16%	12.66%	11.76%	6.23%	10.62%	2.62%	-9.68%	-1.61%
Net Nonoperating Expense Percent (NNEP)	2.51%	2.66%	2.30%	4.63%	3.25%	4.55%	-2.50%	6.27%	3.32%	2.62%
Return On Investment Capital (ROIC_SIMPLE)	-	0.21%	-	-	-	1.12%	-	-	-	-0.30%
Cost of Revenue to Revenue	39.24%	38.55%	35.31%	36.28%	36.49%	40.58%	35.77%	41.80%	42.52%	-89.17%
SG&A Expenses to Revenue	35.89%	35.22%	34.15%	33.26%	31.86%	33.77%	34.94%	38.27%	53.31%	36.58%
R&D to Revenue	9.13%	5.54%	5.55%	6.33%	8.44%	7.49%	7.65%	5.29%	6.83%	8.73%
Operating Expenses to Revenue	66.72%	59.40%	55.42%	53.08%	49.90%	54.32%	49.45%	54.46%	71.31%	191.46%
Earnings before Interest and Taxes (EBIT)	-4.96	1.78	9.86	12	18	6.69	30	2.37	-22	-14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	11	18	26	28	34	23	45	17	-2.61	19
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.80	2.24	2.21	2.36	2.74	2.60	3.22	2.93	3.09	2.88
Price to Tangible Book Value (P/TBV)	28.94	20.77	14.60	6.40	6.48	5.76	6.40	5.46	0.00	0.00
Price to Revenue (P/Rev)	1.98	2.22	1.94	2.41	2.62	2.31	2.82	2.48	2.26	1.89
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	100.22	65.69	42.96	52.60	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	1.00%	1.52%	2.33%	1.90%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.45	1.68	1.66	1.96	2.31	2.30	2.92	2.69	1.94	1.84
Enterprise Value to Revenue (EV/Rev)	2.88	3.04	2.68	2.84	2.94	2.52	2.96	2.60	3.16	2.70
Enterprise Value to EBITDA (EV/EBITDA)	0.00	33.13	16.49	13.71	12.45	11.12	11.79	11.78	21.35	21.14
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	60.00	31.50	26.25	22.87	24.59	101.37	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	85.30	30.94	27.68	32.27	36.67	214.32	4,061.24
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	104.92	27.66	18.90	10.33	13.21	12.43	18.88	25.93
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	39.61	15.02	14.74	13.67	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.85	0.85	0.91	0.72	0.68	0.65	0.60	0.60	1.45	1.46
Long-Term Debt to Equity	0.85	0.84	0.84	0.66	0.63	0.62	0.60	0.59	1.44	1.44
Financial Leverage	0.77	0.60	0.65	0.48	0.43	0.39	0.35	0.21	0.67	0.62
Leverage Ratio	2.29	2.20	2.20	2.09	2.06	2.09	2.06	1.95	2.46	2.47
Compound Leverage Factor	5.65	-7.08	0.48	0.89	1.32	0.30	1.74	-1.88	3.57	2.42
Debt to Total Capital	45.99%	45.84%	47.66%	41.73%	40.52%	39.43%	37.48%	37.31%	59.26%	59.29%
Short-Term Debt to Total Capital	0.14%	0.14%	3.64%	3.47%	3.24%	1.74%	0.17%	0.22%	0.80%	0.87%
Long-Term Debt to Total Capital	45.86%	45.70%	44.01%	38.26%	37.28%	37.70%	37.32%	37.09%	58.46%	58.42%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	3.99%	3.98%	3.83%	3.33%	3.25%	3.29%	3.26%	3.24%	2.35%	2.36%
Common Equity to Total Capital	50.02%	50.19%	48.51%	54.94%	56.23%	57.28%	59.26%	59.44%	38.39%	38.35%
Debt to EBITDA	-223.66	9.88	5.30	3.73	2.92	2.70	2.20	2.41	7.63	7.95
Net Debt to EBITDA	-179.76	8.04	4.14	1.79	1.10	0.70	0.37	0.33	5.76	6.02
Long-Term Debt to EBITDA	-223.00	9.85	4.90	3.42	2.69	2.58	2.19	2.39	7.53	7.83
Debt to NOPAT	-6.73	-11.60	-71.29	23.24	7.26	6.71	6.03	7.50	76.59	1,526.71
Net Debt to NOPAT	-5.41	-9.45	-55.66	11.16	2.74	1.73	1.00	1.02	57.85	1,156.85
Long-Term Debt to NOPAT	-6.71	-11.57	-65.85	21.31	6.68	6.42	6.01	7.45	75.56	1,504.21
Altman Z-Score	1.39	1.63	1.69	2.20	2.56	2.45	3.11	2.86	1.47	1.46
Noncontrolling Interest Sharing Ratio	4.71%	7.13%	7.25%	6.44%	6.28%	6.24%	6.09%	5.43%	5.61%	5.61%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.79	3.46	2.90	3.74	3.70	3.57	3.95	3.97	2.74	2.72
Quick Ratio	2.41	2.15	1.93	2.72	2.77	2.63	3.00	2.95	1.84	1.93
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-192	-30	-23	-14	6.17	46	71	68	-347	-370
Operating Cash Flow to CapEx	146.80%	-140.22%	912.05%	824.71%	1,849.86%	1,963.14%	0.00%	391.41%	259.23%	662.49%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-46.47	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.67	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.03	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.47	0.41	0.48	0.50	0.55	0.58	0.62	0.61	0.51	0.56
Accounts Receivable Turnover	2.29	2.15	2.34	2.48	2.82	2.97	2.98	3.18	2.96	3.20
Inventory Turnover	1.73	1.48	1.52	1.52	1.62	1.68	1.77	1.81	1.75	0.00
Fixed Asset Turnover	6.87	6.60	7.47	9.11	10.33	11.08	11.27	11.23	11.01	12.11
Accounts Payable Turnover	8.94	5.31	5.20	5.32	6.20	5.50	4.70	5.40	4.70	0.00
Days Sales Outstanding (DSO)	159.33	169.57	155.86	147.01	129.66	122.78	122.43	114.80	123.28	114.01
Days Inventory Outstanding (DIO)	210.90	245.97	239.71	240.79	224.75	217.73	205.70	201.24	208.06	0.00
Days Payable Outstanding (DPO)	40.83	68.74	70.25	68.67	58.90	66.35	77.66	67.60	77.60	0.00
Cash Conversion Cycle (CCC)	329.41	346.80	325.33	319.13	295.50	274.16	250.46	248.43	253.74	114.01
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	562	572	581	584	571	534	524	520	904	901
Invested Capital Turnover	0.61	0.57	0.63	0.70	0.79	0.88	0.94	0.98	0.75	0.86
Increase / (Decrease) in Invested Capital	189	31	29	28	9.33	-37	-56	-64	333	367
Enterprise Value (EV)	816	961	961	1,142	1,320	1,229	1,530	1,399	1,753	1,660
Market Capitalization	560	703	695	968	1,178	1,127	1,457	1,336	1,255	1,162
Book Value per Share	$17.88	$17.96	$17.97	$22.79	$21.18	$21.17	$21.44	$21.73	$19.29	$19.20
Tangible Book Value per Share	$1.11	$1.94	$2.72	$8.41	$8.96	$9.57	$10.80	$11.66	($10.66)	($9.42)
Total Capital	623	625	649	746	765	756	763	767	1,057	1,053
Total Debt	287	287	309	311	310	298	286	286	627	624
Total Long-Term Debt	286	286	285	285	285	285	285	284	618	615
Net Debt	230	233	241	149	117	77	48	39	473	473
Capital Expenditures (CapEx)	2.47	3.14	2.35	2.50	1.74	2.28	-8.93	4.45	4.81	2.39
Debt-free, Cash-free Net Working Capital (DFCFNWC)	172	192	195	201	195	166	167	170	186	192
Debt-free Net Working Capital (DFNWC)	229	246	263	362	388	387	405	417	340	343
Net Working Capital (NWC)	228	245	239	336	363	374	404	415	331	334
Net Nonoperating Expense (NNE)	5.10	5.52	5.14	8.51	5.56	7.05	-3.61	5.91	9.80	7.21
Net Nonoperating Obligations (NNO)	225	233	241	149	117	77	48	39	473	473
Total Depreciation and Amortization (D&A)	16	17	16	16	16	16	15	15	19	33
Debt-free, Cash-free Net Working Capital to Revenue	60.87%	60.82%	54.30%	49.98%	43.30%	34.17%	32.21%	31.56%	33.57%	31.25%
Debt-free Net Working Capital to Revenue	80.75%	77.65%	73.19%	90.27%	86.26%	79.59%	78.25%	77.40%	61.17%	55.86%
Net Working Capital to Revenue	80.45%	77.38%	66.61%	83.82%	80.75%	76.90%	78.01%	77.09%	59.66%	54.36%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.55)	($0.29)	$0.06	$0.30	$0.46	$0.04	$0.84	($0.14)	($1.27)	($0.47)
Adjusted Weighted Average Basic Shares Outstanding	16.30M	16.26M	16.39M	17.69M	18.88M	18.00M	19.10M	19.32M	19.40M	19.32M
Adjusted Diluted Earnings per Share	($0.55)	($0.29)	$0.06	$0.29	$0.45	$0.05	$0.82	($0.14)	($1.27)	($0.45)
Adjusted Weighted Average Diluted Shares Outstanding	16.30M	16.26M	16.53M	17.86M	19.13M	18.19M	19.42M	19.32M	19.40M	19.32M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	17.46M	17.50M	17.97M	20.29M	20.44M	21.08M	20.97M	21.04M	21.03M	21.77M
Normalized Net Operating Profit after Tax (NOPAT)	-0.68	3.51	7.97	9.41	13	6.10	11	3.87	-14	-4.39
Normalized NOPAT Margin	-0.82%	3.72%	7.46%	8.07%	10.08%	4.63%	7.87%	2.80%	-9.29%	-2.30%
Pre Tax Income Margin	-14.58%	-6.08%	2.03%	4.50%	8.73%	0.72%	18.43%	-1.66%	-21.23%	-7.22%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-2.91	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-1.92	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-3.55	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-2.57	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	-2.08%	-3.39%	-6.18%	-31.52%	12.15%	8.65%	4.57%	6.02%	-22.92%	-8.77%
Augmented Payout Ratio	-4.79%	-7.48%	-22.85%	-117.66%	48.58%	35.21%	32.98%	46.22%	-176.24%	-67.94%

Frequently Asked Questions About ANI Pharmaceuticals' Financials

When does ANI Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, ANI Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has ANI Pharmaceuticals' net income changed over the last 10 years?

ANI Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$18.52 million in 2024, falling from $28.75 million in 2014. The previous period was $18.78 million in 2023.

What is ANI Pharmaceuticals's operating income?

ANI Pharmaceuticals's total operating income in 2024 was $584 thousand, based on the following breakdown:

Total Gross Profit: $614.38 million
Total Operating Expenses: $613.79 million

How has ANI Pharmaceuticals revenue changed over the last 10 years?

Over the last 10 years, ANI Pharmaceuticals' total revenue changed from $55.97 million in 2014 to $614.38 million in 2024, a change of 997.7%.

How much debt does ANI Pharmaceuticals have?

ANI Pharmaceuticals' total liabilities were at $855.17 million at the end of 2024, a 91.4% increase from 2023, and a 614.0% increase since 2014.

How much cash does ANI Pharmaceuticals have?

In the past 10 years, ANI Pharmaceuticals' cash and equivalents has ranged from $7.86 million in 2020 to $221.12 million in 2023, and is currently $144.86 million as of their latest financial filing in 2024.

How has ANI Pharmaceuticals' book value per share changed over the last 10 years?

Over the last 10 years, ANI Pharmaceuticals' book value per share changed from 12.34 in 2014 to 19.20 in 2024, a change of 55.6%.

Related Companies

This page (NASDAQ:ANIP) was last updated on 4/18/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ANI Pharmaceuticals (ANIP) Financials

Frequently Asked Questions About ANI Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ANI Pharmaceuticals (ANIP) Financials

Annual Income Statements for ANI Pharmaceuticals

Quarterly Income Statements for ANI Pharmaceuticals

Annual Cash Flow Statements for ANI Pharmaceuticals

Quarterly Cash Flow Statements for ANI Pharmaceuticals

Annual Balance Sheets for ANI Pharmaceuticals

Quarterly Balance Sheets for ANI Pharmaceuticals

Annual Metrics and Ratios for ANI Pharmaceuticals

Quarterly Metrics and Ratios for ANI Pharmaceuticals

Frequently Asked Questions About ANI Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools